Cassava Sciences
Yahoo Finance • last month
Cassava Sciences, Inc. (SAVA): Jim Cramer Says Eli Lilly Has The Edge
We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are going to take a look at where Cassava Sciences, Inc. (NASDAQ:SAVA) stands against other stocks discussed by Jim Crame... Full story
Yahoo Finance • 2 months ago
Cassava Sciences shares drop in pre-open trade after $40 mln SEC settlement
Investing.com -- Shares of Cassava Sciences, Inc (NASDAQ:SAVA) dropped 11.5% in pre-open trade on Friday following the company's statement that it has reached a $40 million settlement with the U.S. Securities and Exchange Commission (SEC)... Full story
Yahoo Finance • 4 months ago
Why Cassava Sciences Stock Is Skyrocketing Today
Shares of Cassava Sciences(NASDAQ: SAVA) were skyrocketing 29.6% higher as of 10:53 a.m. ET on Monday. The big gain came after executive chairman Rick Barry released an open letter to shareholders, employees, principal investigators, and p... Full story
Yahoo Finance • 11 months ago
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
Cassava Sciences, Inc. Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker “SAVAW” Warrant Holders Who Choose to Exercise During an Early Period Will Receive an Additional... Full story
Yahoo Finance • 11 months ago
3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street
Ascending Bar Chart Line Invest Financial Newspaper Stock Market Quote Rally Bull Getty In less than a week, Wall Street will turn the page on what's been a stellar year for optimists. The 30-component Dow Jones Industrial Average climbed... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby... Full story
Yahoo Finance • last year
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
Enrollment completed for Phase 3 trials evaluating oral simufilam in Alzheimer's. Over 1,900 patients randomized in on-going Phase 3 trials.Top-line results for 52-week Phase 3 trial expected approximately year-end 2024; top-line results f... Full story
Yahoo Finance • last year
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end 2024.Top-line results for on-going, 76-we... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA
NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby... Full story
Yahoo Finance • last year
MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
Safety Finding Based on Blinded MRI Brain Data at Week 40ARIA is a Known Risk Factor for Anti-Amyloid Antibody DrugsMRI Data Presented at the 16th CTAD Conference in Boston, MA AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Cassava Sc... Full story
Yahoo Finance • last year
Investigation of Cassava Sciences, Inc. (SAVA) Announced by Holzer & Holzer, LLC
ATLANTA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) complied with federal securities laws. On October 12, 2023, Science reported tha... Full story
Yahoo Finance • last year
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
CUNY’s report makes no findings of data manipulation.The “egregious misconduct” cited in the report relates to internal record-keeping failures at CUNY.CUNY’s report finds that internal record-keeping failures “prevented us [CUNY] from mak... Full story
Yahoo Finance • last year
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
AUSTIN, Texas, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that Remi Barbier, President & Chief Executive Of... Full story
Yahoo Finance • last year
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately 1,100 Patients. AUSTIN, Texas, Oct. 02... Full story
Yahoo Finance • last year
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials. The DSMB Recommended the Phase 3 Trials of Simufilam Continue as Planned, With... Full story
Yahoo Finance • last year
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
New cell biology data from Europe shows simufilam interrupts a pathogenic signaling pathway in Alzheimer’s disease.Results corroborate prior research from other academic researchers.These data once again confirm the biological activity of... Full story
Yahoo Finance • last year
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
AUSTIN, Texas, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present at the follo... Full story
Yahoo Finance • last year
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild Alzheimer’s Disease.In Mild Alzheimer’s, Simufilam Improved Cognition Scores Over 6 Mont... Full story
Yahoo Finance • last year
New Research Shows Simufilam Suppresses Overactive mTOR
Overactive mTOR Plays a Key Role in Aging and Alzheimer’s Disease. Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect. Research is Published in Frontiers in Aging, a Peer-reviewed Journal. AUSTIN, Texas, June 27, 2... Full story
Yahoo Finance • last year
New Publication Highlights Basic Science Supporting Simufilam
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research, a Peer-Reviewed Journal. AUSTIN, Texas, June 12, 2023 (GLOBE NEWSWIRE) -- Cass... Full story
